This week Steve welcomes fellow Oxford alum, Talia Cohen Solal, CEO and Co-Founder of Genetika+, the company using tech to tailor depression treatment.


Talia Cohen Solal, Ph.D., CEO and Co-founder: During her 10-year academic career across Oxford, UCL and Columbia University, Talia led the development neural models of mental illnesses and drug development platforms for unique/personalized forms of diseases. She developed and patented new drug screening methodologies and compounds. She has continuously secured her own funding, while publishing 10 papers and filing 4 patents. She then led the scientific program as Principle Scientist at Pairnomix in Minneapolis, a White-House Endorsed early-stage company developing personalized medicine tools for rare-genetic diseases. In her role as CEO of Genetika+, she has won the top prizes in the MassChallenge Accelerator, Avon’s European Woman’s Startup Competition and GroundUp Ventures MarchMadness Competition, Israel BrainTech and EY Digital Health.



Website: https://www.genetikaplus.com/
Twitter:   / genetikaplus  
Facebook:   / genetikaplus  
LinkedIn:   / genetika